Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 133

1.

Pheochromocytoma-Induced Takotsubo Cardiomyopathy.

Afana M, Panchal RJ, Simon RM, Hejab A, Lahiri SW, Khandelwal AK, Hudson MP.

Tex Heart Inst J. 2019 Apr 1;46(2):124-127. doi: 10.14503/THIJ-17-6407. eCollection 2019 Apr.

2.

D3Oncoprint: Stand-Alone Software to Visualize and Dynamically Explore Annotated Genomic Mutation Files.

Palmisano A, Zhao Y, Simon RM.

JCO Clin Cancer Inform. 2018 Dec;2:1-9. doi: 10.1200/CCI.17.00050.

3.

PSA predicts development of incident lower urinary tract symptoms: results from the REDUCE study.

Patel DN, Feng T, Simon RM, Howard LE, Vidal AC, Moreira DM, Castro-Santamaria R, Roehrborn C, Andriole GL, Freedland SJ.

Prostate Cancer Prostatic Dis. 2018 Jun;21(2):238-244. doi: 10.1038/s41391-018-0044-y. Epub 2018 May 23.

PMID:
29795141
4.

On the Design of Combination Cancer Therapy.

Doroshow JH, Simon RM.

Cell. 2017 Dec 14;171(7):1476-1478. doi: 10.1016/j.cell.2017.11.035.

5.

Predictors of operative time during radical retropubic prostatectomy and robot-assisted laparoscopic prostatectomy.

Simon RM, Howard LE, Moreira DM, Terris MK, Kane CJ, Aronson WJ, Amling CL, Cooperberg MR, Freedland SJ.

Int J Urol. 2017 Aug;24(8):618-623. doi: 10.1111/iju.13393. Epub 2017 Jul 11.

6.

Does Peak Urine Flow Rate Predict the Development of Incident Lower Urinary Tract Symptoms in Men with Mild to No Current Symptoms? Results from REDUCE.

Simon RM, Howard LE, Moreira DM, Roehrborn C, Vidal A, Castro-Santamaria R, Freedland SJ.

J Urol. 2017 Sep;198(3):650-656. doi: 10.1016/j.juro.2017.04.075. Epub 2017 Apr 17.

PMID:
28428110
7.

The association between sexual function and prostate cancer risk in US veterans.

Zapata DF, Howard LE, Frank J, Simon RM, Hoyo C, Grant DJ, Freedland SJ, Vidal AC.

Asian J Androl. 2017 Mar-Apr;19(2):191-195. doi: 10.4103/1008-682X.184869.

8.

OpenGeneMed: a portable, flexible and customizable informatics hub for the coordination of next-generation sequencing studies in support of precision medicine trials.

Palmisano A, Zhao Y, Li MC, Polley EC, Simon RM.

Brief Bioinform. 2017 Sep 1;18(5):723-734. doi: 10.1093/bib/bbw059.

PMID:
27422621
9.

Efficiency of Prostate Cancer Diagnosis by MR/Ultrasound Fusion-Guided Biopsy vs Standard Extended-Sextant Biopsy for MR-Visible Lesions.

Siddiqui MM, George AK, Rubin R, Rais-Bahrami S, Parnes HL, Merino MJ, Simon RM, Turkbey B, Choyke PL, Wood BJ, Pinto PA.

J Natl Cancer Inst. 2016 Apr 29;108(9). pii: djw039. doi: 10.1093/jnci/djw039. Print 2016 Sep.

10.

Amount, Source, and Quality of Support as Predictors of Women's Birth Evaluations.

Simon RM, Johnson KM, Liddell J.

Birth. 2016 Sep;43(3):226-32. doi: 10.1111/birt.12227. Epub 2016 Mar 17.

PMID:
26991407
11.

Does Prostate Size Predict the Development of Incident Lower Urinary Tract Symptoms in Men with Mild to No Current Symptoms? Results from the REDUCE Trial.

Simon RM, Howard LE, Moreira DM, Roehrborn C, Vidal AC, Castro-Santamaria R, Freedland SJ.

Eur Urol. 2016 May;69(5):885-91. doi: 10.1016/j.eururo.2015.12.002. Epub 2015 Dec 24.

PMID:
26724841
12.

Effect of utilization of veno-venous bypass vs. cardiopulmonary bypass on complications for high level inferior vena cava tumor thrombectomy and concomitant radical nephrectomy.

Simon RM, Kim T, Espiritu P, Kurian T, Sexton WJ, Pow-Sang JM, Sverrisson E, Spiess PE.

Int Braz J Urol. 2015 Sep-Oct;41(5):911-9. doi: 10.1590/S1677-5538.IBJU.2014.0371.

13.

Analytical Validation and Application of a Targeted Next-Generation Sequencing Mutation-Detection Assay for Use in Treatment Assignment in the NCI-MPACT Trial.

Lih CJ, Sims DJ, Harrington RD, Polley EC, Zhao Y, Mehaffey MG, Forbes TD, Das B, Walsh WD, Datta V, Harper KN, Bouk CH, Rubinstein LV, Simon RM, Conley BA, Chen AP, Kummar S, Doroshow JH, Williams PM.

J Mol Diagn. 2016 Jan;18(1):51-67. doi: 10.1016/j.jmoldx.2015.07.006. Epub 2015 Nov 18.

14.

Do all men with pathological Gleason score 8-10 prostate cancer have poor outcomes? Results from the SEARCH database.

Fischer S, Lin D, Simon RM, Howard LE, Aronson WJ, Terris MK, Kane CJ, Amling CL, Cooperberg MR, Freedland SJ, Vidal AC.

BJU Int. 2016 Aug;118(2):250-7. doi: 10.1111/bju.13319. Epub 2015 Oct 8.

15.

Adverse pathology and undetectable ultrasensitive prostate-specific antigen after radical prostatectomy: is adjuvant radiation warranted?

Simon RM, Howard LE, Freedland SJ, Aronson WJ, Terris MK, Kane CJ, Amling CL, Cooperberg MR, Vidal AC.

BJU Int. 2016 Jun;117(6):897-903. doi: 10.1111/bju.13182. Epub 2015 Jun 23.

16.

GeneMed: An Informatics Hub for the Coordination of Next-Generation Sequencing Studies that Support Precision Oncology Clinical Trials.

Zhao Y, Polley EC, Li MC, Lih CJ, Palmisano A, Sims DJ, Rubinstein LV, Conley BA, Chen AP, Williams PM, Kummar S, Doroshow JH, Simon RM.

Cancer Inform. 2015 Mar 19;14(Suppl 2):45-55. doi: 10.4137/CIN.S17282. eCollection 2015. Review.

17.

The association of exercise with both erectile and sexual function in black and white men.

Simon RM, Howard L, Zapata D, Frank J, Freedland SJ, Vidal AC.

J Sex Med. 2015 May;12(5):1202-10. doi: 10.1111/jsm.12869. Epub 2015 Mar 20.

PMID:
25801073
18.

Use of serial multiparametric magnetic resonance imaging in the management of patients with prostate cancer on active surveillance.

Walton Diaz A, Shakir NA, George AK, Rais-Bahrami S, Turkbey B, Rothwax JT, Stamatakis L, Hong CW, Siddiqui MM, Okoro C, Raskolnikov D, Su D, Shih J, Han H, Parnes HL, Merino MJ, Simon RM, Wood BJ, Choyke PL, Pinto PA.

Urol Oncol. 2015 May;33(5):202.e1-202.e7. doi: 10.1016/j.urolonc.2015.01.023. Epub 2015 Mar 6.

PMID:
25754621
19.

Application of molecular profiling in clinical trials for advanced metastatic cancers.

Kummar S, Williams PM, Lih CJ, Polley EC, Chen AP, Rubinstein LV, Zhao Y, Simon RM, Conley BA, Doroshow JH.

J Natl Cancer Inst. 2015 Feb 6;107(4). pii: djv003. doi: 10.1093/jnci/djv003. Print 2015 Apr.

20.

Clinical implications of a multiparametric magnetic resonance imaging based nomogram applied to prostate cancer active surveillance.

Siddiqui MM, Truong H, Rais-Bahrami S, Stamatakis L, Logan J, Walton-Diaz A, Turkbey B, Choyke PL, Wood BJ, Simon RM, Pinto PA.

J Urol. 2015 Jun;193(6):1943-1949. doi: 10.1016/j.juro.2015.01.088. Epub 2015 Jan 26.

21.

Comparison of MR/ultrasound fusion-guided biopsy with ultrasound-guided biopsy for the diagnosis of prostate cancer.

Siddiqui MM, Rais-Bahrami S, Turkbey B, George AK, Rothwax J, Shakir N, Okoro C, Raskolnikov D, Parnes HL, Linehan WM, Merino MJ, Simon RM, Choyke PL, Wood BJ, Pinto PA.

JAMA. 2015 Jan 27;313(4):390-7. doi: 10.1001/jama.2014.17942.

22.

Randomized Trial of Oral Cyclophosphamide and Veliparib in High-Grade Serous Ovarian, Primary Peritoneal, or Fallopian Tube Cancers, or BRCA-Mutant Ovarian Cancer.

Kummar S, Oza AM, Fleming GF, Sullivan DM, Gandara DR, Naughton MJ, Villalona-Calero MA, Morgan RJ Jr, Szabo PM, Youn A, Chen AP, Ji J, Allen DE, Lih CJ, Mehaffey MG, Walsh WD, McGregor PM 3rd, Steinberg SM, Williams PM, Kinders RJ, Conley BA, Simon RM, Doroshow JH.

Clin Cancer Res. 2015 Apr 1;21(7):1574-82. doi: 10.1158/1078-0432.CCR-14-2565. Epub 2015 Jan 14.

23.

Radical prostatectomy versus radiation therapy: can pretreatment nomograms be used to select the appropriate prostate cancer treatment?

Simon RM, Salama JK, Freedland SJ.

Eur Urol. 2015 Feb;67(2):210-1. doi: 10.1016/j.eururo.2014.10.009. Epub 2014 Oct 28. No abstract available.

PMID:
25457494
24.

Spinal Cord Injury survey to determine pressure ulcer vulnerability in the outpatient population.

Gould LJ, Olney CM, Nichols JS, Block AR, Simon RM, Guihan M.

Med Hypotheses. 2014 Nov;83(5):552-8. doi: 10.1016/j.mehy.2014.08.027. Epub 2014 Sep 6.

PMID:
25241921
25.

Editorial Comment to Significance of early prostate-specific antigen values after salvage radiotherapy in recurrent prostate cancer patients treated with surgery.

Simon RM, Freedland SJ, Vidal AC.

Int J Urol. 2015 Jan;22(1):88. doi: 10.1111/iju.12621. Epub 2014 Sep 10. No abstract available.

26.

Is the "3+3" dose-escalation phase I clinical trial design suitable for therapeutic cancer vaccine development? A recommendation for alternative design.

Rahma OE, Gammoh E, Simon RM, Khleif SN.

Clin Cancer Res. 2014 Sep 15;20(18):4758-67. doi: 10.1158/1078-0432.CCR-13-2671. Epub 2014 Jul 18.

27.

Diagnostic value of biparametric magnetic resonance imaging (MRI) as an adjunct to prostate-specific antigen (PSA)-based detection of prostate cancer in men without prior biopsies.

Rais-Bahrami S, Siddiqui MM, Vourganti S, Turkbey B, Rastinehad AR, Stamatakis L, Truong H, Walton-Diaz A, Hoang AN, Nix JW, Merino MJ, Wood BJ, Simon RM, Choyke PL, Pinto PA.

BJU Int. 2015 Mar;115(3):381-8. doi: 10.1111/bju.12639. Epub 2014 Sep 15.

28.

Criteria for the use of omics-based predictors in clinical trials: explanation and elaboration.

McShane LM, Cavenagh MM, Lively TG, Eberhard DA, Bigbee WL, Williams PM, Mesirov JP, Polley MY, Kim KY, Tricoli JV, Taylor JM, Shuman DJ, Simon RM, Doroshow JH, Conley BA.

BMC Med. 2013 Oct 17;11:220. doi: 10.1186/1741-7015-11-220.

29.

Criteria for the use of omics-based predictors in clinical trials.

McShane LM, Cavenagh MM, Lively TG, Eberhard DA, Bigbee WL, Williams PM, Mesirov JP, Polley MY, Kim KY, Tricoli JV, Taylor JM, Shuman DJ, Simon RM, Doroshow JH, Conley BA.

Nature. 2013 Oct 17;502(7471):317-20. doi: 10.1038/nature12564.

30.

Considerations for the successful co-development of targeted cancer therapies and companion diagnostics.

Fridlyand J, Simon RM, Walrath JC, Roach N, Buller R, Schenkein DP, Flaherty KT, Allen JD, Sigal EV, Scher HI.

Nat Rev Drug Discov. 2013 Oct;12(10):743-55. doi: 10.1038/nrd4101. Epub 2013 Sep 6. Review.

PMID:
24008432
31.

The exomes of the NCI-60 panel: a genomic resource for cancer biology and systems pharmacology.

Abaan OD, Polley EC, Davis SR, Zhu YJ, Bilke S, Walker RL, Pineda M, Gindin Y, Jiang Y, Reinhold WC, Holbeck SL, Simon RM, Doroshow JH, Pommier Y, Meltzer PS.

Cancer Res. 2013 Jul 15;73(14):4372-82. doi: 10.1158/0008-5472.CAN-12-3342. Epub 2013 Jul 15.

32.

Accuracy of multiparametric magnetic resonance imaging in confirming eligibility for active surveillance for men with prostate cancer.

Stamatakis L, Siddiqui MM, Nix JW, Logan J, Rais-Bahrami S, Walton-Diaz A, Hoang AN, Vourganti S, Truong H, Shuch B, Parnes HL, Turkbey B, Choyke PL, Wood BJ, Simon RM, Pinto PA.

Cancer. 2013 Sep 15;119(18):3359-66. doi: 10.1002/cncr.28216. Epub 2013 Jul 2.

33.

Chemogenomics profiling of drug targets of peptidoglycan biosynthesis pathway in Leptospira interrogans by virtual screening approaches.

Bhattacharjee B, Simon RM, Gangadharaiah C, Karunakar P.

J Microbiol Biotechnol. 2013 Jun 28;23(6):779-84.

34.

How to develop treatments for biologically heterogeneous "diseases".

Simon RM.

Clin Cancer Res. 2012 Aug 1;18(15):4001-3. doi: 10.1158/1078-0432.CCR-12-1586. Epub 2012 Jun 7.

35.

Gendered contexts: masculinity, knowledge, and attitudes toward biotechnology.

Simon RM.

Public Underst Sci. 2011 May;20(3):334-46.

PMID:
21796882
36.

Gender differences in knowledge and attitude towards biotechnology.

Simon RM.

Public Underst Sci. 2010 Nov;19(6):642-53.

PMID:
21560540
37.

Optimally splitting cases for training and testing high dimensional classifiers.

Dobbin KK, Simon RM.

BMC Med Genomics. 2011 Apr 8;4:31. doi: 10.1186/1755-8794-4-31.

38.

Using cross-validation to evaluate predictive accuracy of survival risk classifiers based on high-dimensional data.

Simon RM, Subramanian J, Li MC, Menezes S.

Brief Bioinform. 2011 May;12(3):203-14. doi: 10.1093/bib/bbr001. Epub 2011 Feb 15.

39.

Re: Designing a randomized clinical trial to evaluate personalized medicine: a new approach based on risk prediction.

Simon RM, Freidlin B.

J Natl Cancer Inst. 2011 Mar 2;103(5):445; author reply 445-6, discussion 446. doi: 10.1093/jnci/djq552. Epub 2011 Jan 12. No abstract available.

PMID:
21228315
40.

Use of archived specimens in evaluation of prognostic and predictive biomarkers.

Simon RM, Paik S, Hayes DF.

J Natl Cancer Inst. 2009 Nov 4;101(21):1446-52. doi: 10.1093/jnci/djp335. Epub 2009 Oct 8.

41.

How large a training set is needed to develop a classifier for microarray data?

Dobbin KK, Zhao Y, Simon RM.

Clin Cancer Res. 2008 Jan 1;14(1):108-14. doi: 10.1158/1078-0432.CCR-07-0443.

42.
43.

Sample size planning for developing classifiers using high-dimensional DNA microarray data.

Dobbin KK, Simon RM.

Biostatistics. 2007 Jan;8(1):101-17. Epub 2006 Apr 13.

PMID:
16613833
44.

An agenda for clinical trials: clinical trials in the genomic era.

Simon RM.

Clin Trials. 2004;1(5):468-70. No abstract available.

PMID:
16279285
45.

Gene expression patterns and profile changes pre- and post-erlotinib treatment in patients with metastatic breast cancer.

Yang SX, Simon RM, Tan AR, Nguyen D, Swain SM.

Clin Cancer Res. 2005 Sep 1;11(17):6226-32.

46.

Comment on 'Evaluation of the gene-specific dye bias in cDNA microarray experiments'.

Dobbin KK, Shih JH, Simon RM.

Bioinformatics. 2005 Jun 15;21(12):2803-4. Epub 2005 Apr 7. No abstract available.

PMID:
15817695
47.

Characterizing dye bias in microarray experiments.

Dobbin KK, Kawasaki ES, Petersen DW, Simon RM.

Bioinformatics. 2005 May 15;21(10):2430-7. Epub 2005 Mar 17.

PMID:
15774555
48.

Interlaboratory comparability study of cancer gene expression analysis using oligonucleotide microarrays.

Dobbin KK, Beer DG, Meyerson M, Yeatman TJ, Gerald WL, Jacobson JW, Conley B, Buetow KH, Heiskanen M, Simon RM, Minna JD, Girard L, Misek DE, Taylor JM, Hanash S, Naoki K, Hayes DN, Ladd-Acosta C, Enkemann SA, Viale A, Giordano TJ.

Clin Cancer Res. 2005 Jan 15;11(2 Pt 1):565-72.

49.

A random variance model for detection of differential gene expression in small microarray experiments.

Wright GW, Simon RM.

Bioinformatics. 2003 Dec 12;19(18):2448-55.

PMID:
14668230
50.

Experimental design of DNA microarray experiments.

Simon RM, Dobbin K.

Biotechniques. 2003 Mar;Suppl:16-21. No abstract available.

PMID:
12664680

Supplemental Content

Loading ...
Support Center